

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

116	i
Mid	3
11/18	,

Applicants: Rodriguez et al.	) Group Art Unit: 1614
Attorney Docket No.: 31140-B	)
Filed: January 18, 2002	) )
For: Prevention of Ovarian Cancer by Administration of a Vitamin D Compound	) ) )

## RESPONSE TO RESTRICTION AND/OR ELECTION REQUIREMENT

To: Assistant Commissioner For Patents

Washington, DC 20231

Dear Sir:

In response to the Office Action of March 26, 2003, applicants elect a combination of the Vitamin-D compound 1,25-dihydroxyvitamin  $D_3$  and the hormone norethindrone. Applicants respectfully traverse the election/restriction requirement.

Respectfully submitted,

Dated: June 26, 2003

Raymond N/Nimród

ROPER & QUIGG

Reg. No. 31,987

200 South Michigan Avenue
Suite 1000

Chicago, Illinois 60604 Telephone: (312) 408-0855 Facsimile: (312) 408-0865 PECTIVE 1600/29